<div id="readability-page-1"><div> By Connor Hart <pre></pre> Shares of Zymeworks and Jazz Pharmaceuticals climbed after the companies released what they called positive topline results from a late-stage trial of their treatment for certain cancers, including of the stomach, gastroesophageal junction and esophagus. Zymeworks' stock rose 59%, to $29.45, in premarket trading Monday, while Jazz Pharmaceuticals' stock gained 31%, to $184.99. Through Friday's close, shares of Zymeworks are up nearly 27% so far this year, and shares of Jazz Pharmaceuticals are up nearly 15%. The companies said before the bell that the safety profile of their treatment, zanidatamab-hrii, used in combination with chemotherapy as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma was generally consistent with the known safety profile of each agent. The recent trial results support the overall benefit-risk of the drug for use in this indication, the companies added. The companies expect to submit a supplemental biologics license application in the first half of 2026 to support zanidatamab-hrii as a first-line treatment. The treatment is currently approved in the U.S., Europe and China for use in second-line biliary tract cancer and is marketed under the trade name Ziihera. BeOne Medicines is helping to develop and commercialize the treatment. <pre></pre> Write to Connor Hart at connor.hart@wsj.com <pre></pre> (END) Dow Jones Newswires November 17, 2025 07:16 ET (12:16 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

爵士制药

ZYME

Zymeworks 和爵士制药的股票在宣布其癌症治疗药物 zanidatamab-hrii 的积极三期临床试验结果后大幅上涨。Zymeworks 的股价上涨了 59%，达到 29.45 美元，而爵士制药的股价上涨了 31%，达到 184.99 美元。该治疗与化疗联合用于 HER2 阳性胃食管腺癌，显示出一致的安全性。两家公司计划在 2026 年提交补充生物制剂许可申请。该治疗已在二线胆道癌中以 Ziihera 的名称获得批准

Zymeworks 和 Jazz Pharmaceuticals 的股价在癌症治疗的三期试验结果显示积极后上涨